| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa0400af6cecb60e4e0b56355b484e84 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F13-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0478
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-5027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C201-08 |
| filingDate |
2018-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_027503b706a6742333f2202095847329
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fcfcd4d92e797700ace9c8f78c78de4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87adc45bfc14fe01849ad21b1637156c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34495ac9a91517475e5319989ee7176f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93693f7d2d1c480754962d4e048b8afb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97a519315747533f51539b93227598ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bda1a5b07376acca8fcbed75dbc0faa1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27b0382b69c00a1f16849b22ac38f61f |
| publicationDate |
2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3075958-A1 |
| titleOfInvention |
Pharmaceutical composition comprising tetrofosmin and pharmaceutically acceptable salts thereof |
| abstract |
The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with 99mTc -pertechnetate solution gives a stable 99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio- distribution. |
| priorityDate |
2017-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |